Current Advances and Applications of Retinal Organoids.

Dan-Ni Zhou, Shu-Guang Yang, Saijilafu, Feng-Quan Zhou

Abstract readReview

In one paragraph

Review in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dan-Ni Zhou *Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, 310015, China.

Shu-Guang Yang *Center for Translational Neural Regeneration Research, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.ORCID http://orcid.org/0000-0001-7028-9688

SaijilafuKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, 310015, China. saijlf@hzcu.edu.cn.ORCID http://orcid.org/0000-0003-2290-9808

Feng-Quan ZhouCenter for Translational Neural Regeneration Research, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China. fzhou4@zju.edu.cn.ORCID http://orcid.org/0000-0002-1525-9969

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal organoids (ROs) are three-dimensional in vitro models that replicate the specific cellular composition and inner structure of the retina. Currently, ROs derived from human pluripotent stem cells (hPSCs) have been shown to mimic both the structure and function of the human retina. Furthermore, ROs function as a powerful model system for researchers, facilitating the investigation of the pathogenesis and treatment strategies of retinal diseases. Despite their development for over a decade, ROs remain limited in terms of complexity and clinical application. This review summarizes recent advances in the development of retinal differentiation methods and underscores their potential applications in disease modeling, gene therapy, cell transplantation, and drug screening. In addition, it proposes research directions that are geared towards advancing RO methodologies to further broaden their applications.

Indexed as

OrganoidsRetinaAnimalsCell DifferentiationHumansPluripotent Stem CellsRetinal Diseases3D differentiationCell transplantationDisease modelingDrug screeningGene therapyHuman pluripotent stem cellsRetinal organoids

Identifiers

PMID41654672

DOI10.1088/1758-5090/acc761

PMCPMC13158345

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.